Drug
Dupilumab Sar231893 Regn668
Dupilumab Sar231893 Regn668: highest development phase Phase 2, developed by Sanofi. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Sanofi
Trials
| Drug | Phase | Indication |
|---|---|---|
| Dupilumab SAR231893/REGN668 NCT02573233 | Phase 2 | Asthma |
Latest
No recent events.
Follow Dupilumab Sar231893 Regn668 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.